Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Dongwha Pharm Co., Ltd. is a pharmaceutical company primarily engaged in the research, development, manufacturing, and marketing of medicinal products. Established in South Korea, the company has a rich history and is known for its contributions to the healthcare industry. Dongwha Pharm's product portfolio includes over-the-counter drugs, prescription medications, health supplements, and healthcare products. The company operates within both domestic and international markets, offering a broad range of pharmaceuticals that cater to diverse medical needs. Dongwha Pharm Co., Ltd. places a strong emphasis on innovation and quality, investing significantly in research and development to ensure the effectiveness and safety of its products. It serves a wide array of therapeutic areas including cardiovascular, gastrointestinal, and respiratory health, among others. As a key player in the South Korean pharmaceutical industry, Dongwha Pharm contributes to public health advancements and economic vitality through its expansive product line and commitment to scientific research. The company actively participates in the global pharmaceutical supply chain, maintaining partnerships and collaborations that enhance its competitive position in the market.
₩5,020.00
₩50.00 (-0.99%)
Live · 05:26 PM
Operating margin is thin at 0.05%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 6.8%, steady but not accelerating. Margins contracted 2.8pp, which offsets some of the top-line progress.
Negative free cash flow of -₩39.60B. The business is consuming cash, not generating it.
8.4x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
₩501.33B
▲ +6.8% YoY
Net Income (TTM)
₩14.30B
▲ +79.0% YoY
Op. Margin
1.84%
▼ -2.8pp YoY
ROIC
0.03%
▼ -1.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-₩32.01B
▲ +49.3% YoY
Op. Cash Flow (TTM)
₩11.67B
▲ +79.1% YoY
Net Debt
₩94.04B
Cash & Equiv.
₩24.37B
3Y CAGR: +13.4%
Continue Research
A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in .
On quality, Dongwha Pharm Co. scores 31/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 3.6%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Dongwha Pharm Co. scores 31 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 1.8% operating margin and a 0.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Dongwha Pharm Co. pays a regular dividend of about KRW 179.76 per share per year (typically in quarterly installments), a yield of roughly 3.6% at the current price. That is a payout ratio of about 34.9% of earnings, so the dividend is amply covered by earnings. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For 000020.XKRX's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. you should weigh 000020.XKRX's valuation and scores 31/100 on quality (lower-quality). It also yields about 3.6%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.